Literature DB >> 7033148

Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies.

B S Wilson, K Imai, P G Natali, S Ferrone.   

Abstract

The monoclonal antibodies 225.28S and 465.12 to human melanoma-associated antigens have been tested with a large variety of surgically removed skin lesions and malignant tumors as well as with a panel of cultured cell lines in serological and immunochemical assays. The antibody 225.28S reacts with a plasma membrane antigen while the antibody 465.12 detects a cytoplasmic antigen. Both antibodies fail to react with melanocytes from normal skin as well as benign skin lesions but react with nevi, melanoma cells and some skin carcinomas. Analysis with surgically removed tumors and cultured human cell lines indicated that the plasma membrane antigen is restricted to skin lesions whereas the cytoplasmic antigen is synthesized by tumor cells of various histological origins. The plasma membrane antigen is composed of two glyco-polypeptides of 280,000 and greater than 440,000 daltons, while the cytoplasmic antigen consists of 4 glycopolypeptides of 94,000, 75,000, 70,000 and 25,000 daltons. None of these components are bridged by disulfide bonds. The cytoplasmic antigen was readily detected in the spent culture medium of melanoma cell lines in the form of a major 94,000 dalton and a minor 72,000 dalton structure, while the plasma membrane antigen was detectable only after vastly increasing the sensitivity of the assay system.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7033148     DOI: 10.1002/ijc.2910280307

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  65 in total

1.  Radioimmunoscintigraphy of ocular melanoma with 99mTc labelled cutaneous melanoma antibody fragments.

Authors:  J Bomanji; J L Hungerford; M Granowska; K E Britton
Journal:  Br J Ophthalmol       Date:  1987-09       Impact factor: 4.638

Review 2.  CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.

Authors:  Matthew A Price; Leah E Colvin Wanshura; Jianbo Yang; Jennifer Carlson; Bo Xiang; Guiyuan Li; Soldano Ferrone; Arkadiusz Z Dudek; Eva A Turley; James B McCarthy
Journal:  Pigment Cell Melanoma Res       Date:  2011-12       Impact factor: 4.693

3.  Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems.

Authors:  P Garin-Chesa; H R Beresford; A Carrato-Mena; H F Oettgen; L J Old; M R Melamed; W J Rettig
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

4.  Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement.

Authors:  B Wang; Y B Chen; O Ayalon; J Bender; A Garen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

5.  Immunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma.

Authors:  T Cerny; S E Owens; S A Mackenzie; P M Nuttall; A K Gosh; D B Smith; N Thatcher
Journal:  Eur J Nucl Med       Date:  1987

6.  Comparative clinical pharmacology of [111In]-labeled murine monoclonal antibodies.

Authors:  M G Rosenblum; J L Murray; L Lamki; G David; D Carlo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies.

Authors:  Allison S Drake; Michael T Brady; Xin Hui Wang; Sheila J N Sait; Justin C Earp; Sampa Ghoshal Gupta; Soldano Ferrone; Eunice S Wang; Meir Wetzler
Journal:  Cancer Immunol Immunother       Date:  2008-08-02       Impact factor: 6.968

8.  Selective in vitro toxicity of purothionin conjugated to the monoclonal antibody 225.28S to a human high-molecular-weight melanoma-associated antigen.

Authors:  K Imai; T Nakanishi; T Noguchi; A Yachi; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Heterogeneity of primary and metastatic human malignant melanoma as detected with monoclonal antibodies in cryostat sections of biopsies.

Authors:  L Suter; E B Bröcker; J Brüggen; D J Ruiter; C Sorg
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  High-dose, unlabeled, nonspecific antibody pretreatment: influence on specific antibody localization to human melanoma xenografts.

Authors:  R L Wahl; B S Wilson; M Liebert; W H Beierwaltes
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.